GOSS GOSSAMER BIO INC revenue, earnings and financials
For the quarter ended June 30, 2026, GOSSAMER BIO INC reported revenue of $9.24M (down 19.6% from a year earlier), net income of $16.9M and diluted EPS of −$0.08; over the last four quarters revenue was $53.3M and net income −$125M; for the fiscal year ended December 2025 revenue was $48.5M, down 57.7% on the year before.
GOSS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $48.5M, gross profit n/a, operating income −$171M, net income −$170M (margin -351.5%), EPS −$0.75
- Fiscal year ended Dec 2024: revenue $115M, gross profit n/a, operating income −$59.9M, net income −$56.5M (margin -49.3%), EPS −$0.25
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$184M, net income −$180M (margin n/a), EPS −$1.18
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$219M, net income −$229M (margin n/a), EPS −$2.71
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$216M, net income −$234M (margin n/a), EPS −$3.13
GOSS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $9.24M (down 19.6% year over year), net income $16.9M, EPS −$0.08
- Quarter ended Mar 31, 2026: revenue $17.0M (up 71.5% year over year), net income −$46.7M, EPS −$0.20
- Quarter ended Dec 31, 2025 (from the annual report): revenue $13.8M (up 47.1% year over year), net income −$47.2M, EPS −$0.21
- Quarter ended Sep 30, 2025: revenue $13.3M (up 40.2% year over year), net income −$48.2M, EPS −$0.21
- Quarter ended Jun 30, 2025: revenue $11.5M (down 88.0% year over year), net income −$38.3M, EPS −$0.17
- Quarter ended Mar 31, 2025: revenue $9.89M, net income −$36.6M, EPS −$0.16
- Quarter ended Dec 31, 2024 (from the annual report): revenue $9.38M, net income −$33.0M, EPS −$0.14
- Quarter ended Sep 30, 2024: revenue $9.48M, net income −$30.8M, EPS −$0.14
- Quarter ended Jun 30, 2024: revenue $95.8M, net income $49.2M, EPS $0.22
- Quarter ended Mar 31, 2024: revenue $0, net income −$41.9M, EPS −$0.19
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$48.1M, EPS $0.00
- Quarter ended Sep 30, 2023: revenue $0, net income −$40.0M, EPS −$0.21
- Quarter ended Jun 30, 2023: revenue $0, net income −$42.5M, EPS −$0.45
- Quarter ended Mar 31, 2023: revenue n/a, net income −$49.2M, EPS −$0.52
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$55.8M, EPS −$0.56
- Quarter ended Sep 30, 2022: revenue n/a, net income −$59.4M, EPS −$0.65
- Quarter ended Jun 30, 2022: revenue n/a, net income −$56.5M, EPS −$0.74
- Quarter ended Mar 31, 2022: revenue n/a, net income −$57.8M, EPS −$0.76
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$56.3M, EPS −$0.75
- Quarter ended Sep 30, 2021: revenue n/a, net income −$60.2M, EPS −$0.80
GOSS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$171M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$3.47M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$159M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$187M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$189M, share buybacks n/a
GOSS balance sheet
- Jun 30, 2026: cash $41.1M, total assets $76.9M, total liabilities $171M, shareholders' equity −$94.0M
- Mar 31, 2026: cash $41.0M, total assets $129M, total liabilities $290M, shareholders' equity −$161M
- Dec 31, 2025: cash $37.7M, total assets $172M, total liabilities $295M, shareholders' equity −$123M
- Sep 30, 2025: cash $8.93M, total assets $209M, total liabilities $291M, shareholders' equity −$82.3M
- Jun 30, 2025: cash $26.3M, total assets $241M, total liabilities $287M, shareholders' equity −$46.1M
- Mar 31, 2025: cash $29.0M, total assets $281M, total liabilities $287M, shareholders' equity −$6.25M
- Dec 31, 2024: cash $46.1M, total assets $315M, total liabilities $286M, shareholders' equity $29.5M, long-term debt $0
- Sep 30, 2024: cash $28.5M, total assets $351M, total liabilities $297M, shareholders' equity $54.1M, long-term debt $0
What is GOSS's revenue?
GOSSAMER BIO INC reported $53.3M of revenue over its last four quarters, through June 30, 2026.
Is GOSS profitable?
No. GOSSAMER BIO INC lost $125M over the last four quarters.
What is GOSS's EPS?
Diluted earnings per share over the last four quarters were −$0.70; −$0.08 in the latest quarter.